{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:35:22Z","timestamp":1753893322519,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>To report our experience of short-term results of drug-coated balloon (DCB) combined with chocolate balloon in the treatment of femoropopliteal artery lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From June 2021 to December 2022, patients with femoropopliteal artery lesions (Rutherford classification 2\u20136) who underwent DCB combined with Chocolate PTA balloon catheter treatment were included. Clinical data of the patients were collected, and follow-up was conducted at 3, 6, and 12 months. The primary patency rate and the freedom from clinically-driven target lesion revascularization (f-TLR) rate were calculated by Kaplan\u2013Meier survival curves.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study included a total of 43 patients (mean age 72.84\u2009\u00b1\u200910.19 years, male proportion 67.4%) with 47 lesions. Among them, 17 lesions (36.2%) presented severe stenosis with an average lesion length of 110.41\u2009\u00b1\u200947.67\u2005mm. Thirty lesions (63.8%) were identified as chronic total occlusions (CTO), with an average occlusion length of 104.13\u2009\u00b1\u200961.12\u2005mm. The Kaplan\u2013Meier survival curve estimated a primary patency rate of 87.2% at 6 months and 78.7% at 12 months. The f-TLR rate at 12 months was 85.1%, estimated by Kaplan\u2013Meier survival curve. The mean ankle-brachial index (ABI) increased from 0.53\u2009\u00b1\u20090.12 before the surgery to 0.87\u2009\u00b1\u20090.12 at 12 months postoperatively, and this difference was statistically significant (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). A total of 91.5% of patients (43\/47) showed a decrease in Rutherford classification at 12 months postoperatively. The proportion of patients with Rutherford class 4\u20136 decreased from 70.2% (33\/47) preoperatively to 4.3% (2\/47) at 12 months postoperatively, and this difference was statistically significant (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). Among the limbs, 34 (72.3%) experienced dissection during the surgery, with 29 cases classified as type B or lower dissection and 5 cases classified as type C or higher (severe dissection) (10.6%). Two limbs (4.3%) required the use of salvage stents. There were no procedure- or device-related deaths within the 12-month period. Twelve limbs (25.5%) underwent minor amputations (toe amputations).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The combination of DCB and chocolate balloon angioplasty has achieved satisfactory patency rates and f-TLR results in 1-year follow-up for the treatment of femoropopliteal artery lesions. However, further confirmation of these findings is needed through multicenter data and long-term follow-up results.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2025.1419127","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T10:39:12Z","timestamp":1743158352000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-term therapeutic efficacy analysis of drug-coated balloon combined with chocolate balloon for the treatment of femoropopliteal artery lesions"],"prefix":"10.3389","volume":"12","author":[{"given":"Rong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao Yun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian Hong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang Feng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng Hui","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3390\/diagnostics13142356","article-title":"Focus on the most common paucisymptomatic vasculopathic population, from diagnosis to secondary prevention of complications","volume":"13","author":"Martelli","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Glob Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European Stroke Organization (ESO) The task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1024\/0301-1526\/a000440","article-title":"Restenosis after endovascular revascularization in peripheral artery disease","volume":"44","author":"Malyar","year":"2015","journal-title":"Vasa"},{"key":"B6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.avsg.2022.09.047","article-title":"Results of new dual-drug coated balloon angioplasty versus POBA for femoropopliteal lesions","volume":"89","author":"Sallustro","year":"2023","journal-title":"Ann Vasc Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ahj.2019.07.014","article-title":"Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease","volume":"217","author":"Long","year":"2019","journal-title":"Am Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1406235","article-title":"Trial of a paclitaxel-coated balloon for femoropopliteal artery disease","volume":"373","author":"Rosenfield","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/1526602817698634","article-title":"Angiographic dissection patterns and patency outcomes after balloon angioplasty for superficial femoral artery disease","volume":"24","author":"Fujihara","year":"2017","journal-title":"J Endovasc Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00270-017-1840-9","article-title":"Early experience with a new concept of angioplasty nitinol-constrained balloon catheter (chocolate((R))) in severely claudicant patients","volume":"41","author":"Sirignano","year":"2018","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s42155-022-00324-z","article-title":"Impact of chocolate percutaneous transluminal angioplasty balloon on vessel preparation in drug-coated balloon angioplasty for femoropopliteal lesion","volume":"5","author":"Shirai","year":"2022","journal-title":"CVIR Endovasc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1161\/01.atv.19.3.538","article-title":"Ankle-arm index as a predictor of cardiovascular disease and mortality in the cardiovascular health study. The cardiovascular health study group","volume":"19","author":"Newman","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/01.RVI.0000220367.62137.e8","article-title":"in vivo MR angiographic quantification of axial and twisting deformations of the superficial femoral artery resulting from maximum hip and knee flexion","volume":"17","author":"Cheng","year":"2006","journal-title":"J Vasc Interv Radiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.avsg.2020.10.005","article-title":"Randomized controlled trial for paclitaxel-coated balloon versus plain balloon angioplasty in dysfunctional hemodialysis vascular access: 12-month outcome from a nonsponsored trial","volume":"72","author":"Pang","year":"2021","journal-title":"Ann Vasc Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jacc.2013.05.079","article-title":"Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease)","volume":"62","author":"Lammer","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1161\/CIRCULATIONAHA.116.022546","article-title":"Percutaneous therapies for peripheral artery disease","volume":"134","author":"Shishehbor","year":"2016","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ahj.2019.12.012","article-title":"Paclitaxel-related balloons and stents for the treatment of peripheral artery disease: insights from the food and drug administration 2019 circulatory system devices panel meeting on late mortality","volume":"222","author":"Dan","year":"2020","journal-title":"Am Heart J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11886-017-0913-3","article-title":"Advances in percutaneous therapies for peripheral artery disease: drug-coated balloons","volume":"19","author":"Al-Bawardy","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.avsg.2021.01.079","article-title":"Drug-coated balloon versus bare nitinol stent in femoropopliteal artery: 12 months outcome from a single center in China","volume":"74","author":"Zhao","year":"2021","journal-title":"Ann Vasc Surg"},{"key":"B20","first-page":"24","article-title":"Novel use of pillows and grooves: the chocolate\u2014PTA balloon catheter","author":"Ward","year":"2014","journal-title":"Endovasc Today"},{"key":"B21","doi-asserted-by":"publisher","first-page":"675899822","DOI":"10.1177\/03000605211006546","article-title":"Association between post-balloon angioplasty dissection and primary patency in complex femoropopliteal artery disease: 2-year clinical outcomes of the AcoArt I trial","volume":"49","author":"Ren","year":"2021","journal-title":"J Int Med Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.23736\/S0021-9509.22.12341-4","article-title":"What should we expect from intravascular ultrasound use for complex femoropopliteal lesions?","volume":"63","author":"Nakama","year":"2022","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3390\/jcdd9110392","article-title":"Income-related peripheral artery disease treatment: a nation-wide analysis from 2009 to 2018","volume":"9","author":"Messiha","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1161\/CIRCULATIONAHA.122.059646","article-title":"Randomized trial of chocolate touch compared with lutonix drug-coated balloon in femoropopliteal lesions (chocolate touch study)","volume":"145","author":"Shishehbor","year":"2022","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jacc.2018.11.039","article-title":"Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease","volume":"73","author":"Bausback","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2025.1419127\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T10:39:26Z","timestamp":1743158366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2025.1419127\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":25,"alternative-id":["10.3389\/fsurg.2025.1419127"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2025.1419127","relation":{},"ISSN":["2296-875X"],"issn-type":[{"type":"electronic","value":"2296-875X"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"1419127"}}